{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T15:18:09Z","timestamp":1795101489184,"version":"4.10.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,7,30]],"date-time":"2015-07-30T00:00:00Z","timestamp":1438214400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13023-015-0305-y","type":"journal-article","created":{"date-parts":[[2015,7,29]],"date-time":"2015-07-29T10:55:00Z","timestamp":1438167300000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["The quality of economic evaluations of ultra-orphan drugs in Europe \u2013 a systematic review"],"prefix":"10.1186","volume":"10","author":[{"given":"Y.","family":"Schuller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. E. M.","family":"Hollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Biegstraaten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,30]]},"reference":[{"key":"305_CR1","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/sj.embor.7400450","volume":"6","author":"A Rinaldi","year":"2005","unstructured":"Rinaldi A. Adopting an orphan. EMBO Rep. 2005;6:507\u201310.","journal-title":"EMBO Rep"},{"key":"305_CR2","unstructured":"OrphaNet. http:\/\/www.orpha.net\/consor\/cgi-bin\/index.php?lng=EN. Accessed May 2015."},{"key":"305_CR3","unstructured":"Excellence NIfC. NICE Citizens Council Report on Ultra Orphan Drugs. London 2004."},{"key":"305_CR4","unstructured":"Orphan incentives. European Medicines Agency. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/regulation\/general\/general_content_000393.jsp. Accessed May 2015."},{"key":"305_CR5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1750-1172-6-42","volume":"6","author":"S Simoens","year":"2011","unstructured":"Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011;6:42.","journal-title":"Orphanet J Rare Dis"},{"key":"305_CR6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/08989621.2013.793120","volume":"20","author":"M Herder","year":"2013","unstructured":"Herder M. When everyone is an orphan: against adopting a U.S.-styled orphan drug policy in Canada. Account Res. 2013;20:227\u201369.","journal-title":"Account Res"},{"key":"305_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2796.2006.01666.x","volume":"260","author":"M Wastfelt","year":"2006","unstructured":"Wastfelt M, Fadeel B, Henter JI. A journey of hope: lessons learned from studies on rare diseases and orphan drugs. J Intern Med. 2006;260:1\u201310.","journal-title":"J Intern Med"},{"key":"305_CR8","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/hec.864","volume":"13","author":"N Devlin","year":"2004","unstructured":"Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ. 2004;13:437\u201352.","journal-title":"Health Econ"},{"key":"305_CR9","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1136\/bmj.329.7459.224","volume":"329","author":"MD Rawlins","year":"2004","unstructured":"Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ. 2004;329:224\u20137.","journal-title":"BMJ"},{"key":"305_CR10","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.healthpol.2005.08.008","volume":"77","author":"HA Dakin","year":"2006","unstructured":"Dakin HA, Devlin NJ, Odeyemi IA. \u201cYes\u201d, \u201cNo\u201d or \u201cYes, but\u201d? Multinomial modelling of NICE decision-making. Health Policy. 2006;77:352\u201367.","journal-title":"Health Policy"},{"key":"305_CR11","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1017\/S0266462305050324","volume":"21","author":"S Evers","year":"2005","unstructured":"Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria. Int J Technol Assess Health Care. 2005;21:240\u20135.","journal-title":"Int J Technol Assess Health Care"},{"key":"305_CR12","unstructured":"Higgins JPT GS. Cochrane Handbook for Systematic Reviews of Interventions vol Version 5.1.0. The Cochrane collaboration; 2011."},{"key":"305_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1750-1172-9-51","volume":"9","author":"L van Dussen","year":"2014","unstructured":"van Dussen L, Biegstraaten M, Hollak CE, Dijkgraaf MG. Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease. Orphanet J Rare Dis. 2014;9:51.","journal-title":"Orphanet J Rare Dis"},{"key":"305_CR14","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2165\/00019053-199405060-00001","volume":"5","author":"E Beutler","year":"1994","unstructured":"Beutler E, Garber AM. Alglucerase for Gaucher\u2019s disease: dose, costs and benefits. Pharmacoeconomics. 1994;5:453\u20139.","journal-title":"Pharmacoeconomics"},{"key":"305_CR15","doi-asserted-by":"publisher","first-page":"635","DOI":"10.2165\/11317820-000000000-00000","volume":"29","author":"MC Garin","year":"2009","unstructured":"Garin MC, Clark L, Chumney EC, Simpson KN, Highland KB. Cost-utility of treatments for pulmonary arterial hypertension: a Markov state-transition decision analysis model. Clin Drug Investig. 2009;29:635\u201346.","journal-title":"Clin Drug Investig"},{"key":"305_CR16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2165\/00019053-200725030-00003","volume":"25","author":"DF Moore","year":"2007","unstructured":"Moore DF, Ries M, Forget EL, Schiffmann R. Enzyme replacement therapy in orphan and ultra-orphan diseases: the limitations of standard economic metrics as exemplified by Fabry-Anderson disease. Pharmacoeconomics. 2007;25:201\u20138.","journal-title":"Pharmacoeconomics"},{"key":"305_CR17","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1177\/0272989X9701700210","volume":"17","author":"N Soohoo","year":"1997","unstructured":"Soohoo N, Schneider JA, Kaplan RM. A cost-effectiveness analysis of the orphan drug cysteamine in the treatment of infantile cystinosis. Med Decis Making. 1997;17:193\u20138.","journal-title":"Med Decis Making"},{"key":"305_CR18","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1378\/chest.124.6.2087","volume":"124","author":"KB Highland","year":"2003","unstructured":"Highland KB, Strange C, Mazur J, Simpson KN. Treatment of Pulmonary Arterial Hypertension: A Preliminary Decision Analysis. Chest. 2003;124:2087\u201392.","journal-title":"Chest"},{"key":"305_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1590\/S0124-00642012000100012","volume":"14","author":"HE Castro-Jaramillo","year":"2012","unstructured":"Castro-Jaramillo HE. The cost-effectiveness of enzyme replacement therapy (ERT) for the infantile form of Pompe disease: comparing a high-income country\u2019s approach (England) to that of a middle-income one (Colombia). Revista de Salud Publica. 2012;14:143\u201355.","journal-title":"Revista de Salud Publica"},{"key":"305_CR20","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1111\/j.1524-4733.2009.00568.x","volume":"12","author":"MD Stevenson","year":"2009","unstructured":"Stevenson MD, Macdonald FC, Langley J, Hunsche E, Akehurst R. The cost-effectiveness of bosentan in the United Kingdom for patients with pulmonary arterial hypertension of WHO functional class III. Value Health. 2009;12:1100\u20135.","journal-title":"Value Health"},{"key":"305_CR21","first-page":"iii","volume":"10","author":"M Connock","year":"2006","unstructured":"Connock M, Juarez-Garcia A, Frew E, Mans A, Dretzke J, Fry-Smith A, et al. A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry\u2019s disease and mucopolysaccharidosis type 1. Health Technol Assess. 2006;10:iii\u2013iv. ix-113.","journal-title":"Health Technol Assess"},{"key":"305_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta16390","volume":"16","author":"K Wyatt","year":"2012","unstructured":"Wyatt K, Henley W, Anderson L, Anderson R, Nikolaou V, Stein K, et al. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders. Health Technol Assess. 2012;16:1\u2013543.","journal-title":"Health Technol Assess"},{"key":"305_CR23","volume-title":"Prevalence and prognosis of paroxysmal nocturnal haemoglobinuria and the clinical and cost-effectiveness of eculizumab","author":"M Connock","year":"2008","unstructured":"Connock M, Wang D, Fry-Smith A, Moore D. Prevalence and prognosis of paroxysmal nocturnal haemoglobinuria and the clinical and cost-effectiveness of eculizumab. 2008."},{"key":"305_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1750-1172-9-75","volume":"9","author":"TA Kanters","year":"2014","unstructured":"Kanters TA, Hoogenboom-Plug I, Rutten-Van Molken MP, Redekop WK, van der Ploeg AT, Hakkaart L. Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease. Orphanet J Rare Dis. 2014;9:75.","journal-title":"Orphanet J Rare Dis"},{"key":"305_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1750-1172-8-29","volume":"8","author":"SM Rombach","year":"2013","unstructured":"Rombach SM, Hollak CE, Linthorst GE, Dijkgraaf MG. Cost-effectiveness of enzyme replacement therapy for Fabry disease. Orphanet J Rare Dis. 2013;8:29.","journal-title":"Orphanet J Rare Dis"},{"key":"305_CR26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2165\/11630780-000000000-00000","volume":"10","author":"A Roman","year":"2012","unstructured":"Roman A, Barbera JA, Escribano P, Sala ML, Febrer L, Oyaguez I, et al. Cost effectiveness of prostacyclins in pulmonary arterial hypertension. Appl Health Econ Health Pol. 2012;10:175\u201388.","journal-title":"Appl Health Econ Health Pol"},{"key":"305_CR27","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2165\/00019053-200624090-00007","volume":"24","author":"JH Wlodarczyk","year":"2006","unstructured":"Wlodarczyk JH, Cleland LG, Keogh AM, McNeil KD, Perl K, Weintraub RG, et al. Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: cost effectiveness and risk sharing. Pharmacoeconomics. 2006;24:903\u201315.","journal-title":"Pharmacoeconomics"},{"key":"305_CR28","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1177\/0272989X14539731","volume":"34","author":"D Coyle","year":"2014","unstructured":"Coyle D, Cheung MC, Evans GA. Opportunity cost of funding drugs for rare diseases: the cost-effectiveness of eculizumab in paroxysmal nocturnal hemoglobinuria. Med Decis Making. 2014;34:1016\u201329.","journal-title":"Med Decis Making"},{"key":"305_CR29","first-page":"15","volume":"3","author":"R Hyde","year":"2010","unstructured":"Hyde R, Dobrovolny D. Orphan drug pricing and payer management in the United States: are we approaching the tipping point? Am Health Drug Benefit. 2010;3:15\u201323.","journal-title":"Am Health Drug Benefit"},{"key":"305_CR30","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1177\/0272989X12454577","volume":"32","author":"JJ Caro","year":"2012","unstructured":"Caro JJ, Briggs AH, Siebert U, Kuntz KM, Force I-SMGRPT. Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Making. 2012;32:667\u201377.","journal-title":"Med Decis Making"},{"key":"305_CR31","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.jval.2012.06.016","volume":"15","author":"M Roberts","year":"2012","unstructured":"Roberts M, Russell LB, Paltiel AD, Chambers M, McEwan P, Krahn M, et al. Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--2. Value Health. 2012;15:804\u201311.","journal-title":"Value Health"},{"key":"305_CR32","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1017\/S0266462307051550","volume":"23","author":"MF Drummond","year":"2007","unstructured":"Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care. 2007;23:36\u201342.","journal-title":"Int J Technol Assess Health Care"},{"key":"305_CR33","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3389\/fphar.2010.00115","volume":"1","author":"S Simoens","year":"2010","unstructured":"Simoens S. How to assess the value of medicines? Front Pharmacol. 2010;1:115.","journal-title":"Front Pharmacol"},{"key":"305_CR34","unstructured":"NICE. Developing NICE highly specialised technologies. National Institute for Health and Care Excellence. 2013. http:\/\/www.nice.org.uk\/aboutnice\/howwework\/devhst\/DevelopingNICEHighlySpecialisedTechnologies.jsp. Accessed July 1st 2015."},{"key":"305_CR35","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1586\/erp.10.33","volume":"10","author":"L Tilson","year":"2010","unstructured":"Tilson L, Barry M. Recent developments in pharmacoeconomic evaluation in Ireland. Expert Rev Pharmacoecon Outcomes Res. 2010;10:221\u20134.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"305_CR36","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2165\/00019053-200119110-00004","volume":"19","author":"B George","year":"2001","unstructured":"George B, Harris A, Mitchell A. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996). Pharmacoeconomics. 2001;19:1103\u20139.","journal-title":"Pharmacoeconomics"},{"key":"305_CR37","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40273-014-0216-0","volume":"33","author":"A Beresniak","year":"2015","unstructured":"Beresniak A, Medina-Lara A, Auray JP, De Wever A, Praet JC, Tarricone R, et al. Validation of the underlying assumptions of the quality-adjusted life-years outcome: results from the ECHOUTCOME European project. Pharmacoeconomics. 2015;33:61\u20139.","journal-title":"Pharmacoeconomics"},{"key":"305_CR38","doi-asserted-by":"publisher","first-page":"DS197","DOI":"10.1097\/00005650-199602000-00008","volume":"34","author":"M Gold","year":"1996","unstructured":"Gold M. Panel on cost-effectiveness in health and medicine. Med Care. 1996;34:DS197\u20139.","journal-title":"Med Care"},{"key":"305_CR39","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1001\/jama.2011.566","volume":"305","author":"PJ Neumann","year":"2011","unstructured":"Neumann PJ. What next for QALYs? Jama. 2011;305:1806\u20137.","journal-title":"Jama"},{"key":"305_CR40","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/S0277-9536(96)00082-2","volume":"43","author":"A Williams","year":"1996","unstructured":"Williams A. QALYS and ethics: a health economist\u2019s perspective. Soc Sci Med. 1996;43:1795\u2013804.","journal-title":"Soc Sci Med"},{"key":"305_CR41","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1001\/jama.2013.278129","volume":"310","author":"BP O'Sullivan","year":"2013","unstructured":"O'Sullivan BP, Orenstein DM, Milla CE. Pricing for orphan drugs: will the market bear what society cannot? JAMA. 2013;310:1343\u20134.","journal-title":"JAMA"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-015-0305-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-015-0305-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-015-0305-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-015-0305-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T17:56:30Z","timestamp":1630605390000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-015-0305-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,30]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["305"],"URL":"https:\/\/doi.org\/10.1186\/s13023-015-0305-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,30]]},"assertion":[{"value":"8 June 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"92"}}